Prostate cancer imaging: positron-emission tomography perspectives

Nevein Ibrahim
Steve Y Cho

Department of Radiology, Nuclear Medicine Section, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

Abstract: There is a pressing demand for more accurate characterization of prostate cancer to provide risk-adapted patient-specific therapy, especially with the recent development of a growing repertoire of treatment options. This trend toward more personalized care has resulted in a need for improved prostate-specific imaging in order to provide image-guided therapy and facilitate treatment monitoring. In addition to these clinical needs, there is a growing vision and challenge for new molecular imaging techniques not only to detect tumors but also provide important information regarding tumor biology and prognosis. This review presents a perspective on prostate cancer imaging, summarizing current conventional imaging approaches with a focus on emerging and future positron emission tomography-based radiotracers at different clinical and preclinical stages of development.

Keywords: prostate cancer, positron-emission tomography, molecular imaging, single photon-emission computed tomography, prostate-specific membrane antigen

Introduction

Prostate cancer is among the most common male cancers, and is considered the second-leading cause of death among American men.1 With the development of widening choices of therapeutic options and in order to provide image-guided therapy, facilitate therapeutic monitoring, and predict clinical outcome, more accurate characterization of prostate cancer is needed. Current NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) incorporate conventional imaging in the initial staging evaluation, as shown in Figure 1 (version 1.2015, http://www.nccn.org). The goal of prostate cancer imaging in the future will be to move beyond clinical management on the basis of current clinical risk factors (stage, serum prostate-specific antigen [PSA] level, and pathologic Gleason score)2 to more individualized patient-adapted therapy based on prognostic biomarkers.3,4 The trend toward more personalized care has resulted in a demand for more specialized imaging biomarkers and imaging techniques. Beyond the need for improved detection of the disease, there is a challenge for molecular imaging to assess its biology (indolent versus aggressive) and treatment response (castration-sensitive from castration-resistant prostate cancer [CRPC]).

This review summarizes imaging approaches in prostate cancer, focusing on current, emerging, and future positron-emission tomography (PET)-based molecular imaging agents in development, with a summary of the agents discussed provided in Table 1 and particular emphasis on their potential for mechanism-based and personalized approaches to disease management.
Initial prostate cancer diagnosis

- DRE
- PSA
- Gleason primary and secondary grade

Initial clinical assessment

- Life expectancy ≤ 5 years and asymptomatic
- Life expectancy > 5 years or symptomatic

Preferred treatment for any therapy is approved clinical trial.

Life expectancy > 5 years and asymptomatic

No further workup or treatment until symptomatic, except in high- or very-high-risk groups

Bone scan if any of these:
- T1 and PSA > 20
- T2 and PSA > 10
- Gleason score ≥ 8
- T3, T4
- Symptomatic

Pelvic CT or MRI if any of these:
- T3, T4
- T1–T2 and nomogram indicated probability of lymph node involvement > 10%

All others: no additional imaging

Staging workup

Suspicious nodes → Consider biopsy

Risk group

- Clinically localized:
  - Very low:
    - T1c
    - Gleason score ≤ 6
    - PSA < 10 ng/mL
  - Fewer than 3 prostate biopsy cores positive, ≤ 50% cancer in each core
  - PSA density < 0.15 ng/mL/L

- Low:
  - ≥ T1–T2a
  - Gleason score ≤ 6
  - PSA < 10 ng/mL

- Intermediate:
  - T2b–T2c or
  - Gleason score 7 or
  - PSA 10–20 ng/mL

- High:
  - ≥ T3a or
  - Gleason score 8–10 or
  - PSA > 20 ng/mL

- Locally advanced:
  - T3b–T4
  - Primary gleason pattern 5 or
  - ≥ 4 cores with gleason score ≥ 10

- Metastatic:
  - Any T, N1
  - Any T, Any N, M1

Figure 1 NCCN guidelines in initial staging of prostate cancer.

Note: Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.1.2015. © 2014 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines© and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. National Comprehensive Cancer Network®, NCCN®, NCCN Guidelines®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.

Abbreviations: DRE, digital rectal exam; PSA, prostate-specific antigen; CT, computed tomography; MRI, magnetic resonance imaging; NCCN, National Comprehensive Cancer Network.

Table 1 Current and future molecular imaging agents in prostate cancer

<table>
<thead>
<tr>
<th>Agents</th>
<th>Half-life</th>
<th>Technique</th>
<th>Mechanism/target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current PET agents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>99mTc-MDP</td>
<td>6 hours</td>
<td>Planar/SPECT</td>
<td>Bisphosphonate analog</td>
</tr>
<tr>
<td>18F-NaF</td>
<td>110 minutes</td>
<td>PET</td>
<td>Chemisorption onto hydroxyapatite</td>
</tr>
<tr>
<td>18F-FDG</td>
<td>110 minutes</td>
<td>PET</td>
<td>Glucose analog</td>
</tr>
<tr>
<td>11C-choline</td>
<td>20.3 minutes</td>
<td>PET</td>
<td>Lipid-metabolism agent associated with overexpression of choline kinase</td>
</tr>
<tr>
<td>18F-choline</td>
<td>110 minutes</td>
<td>PET</td>
<td>Lipid-metabolism agent associated with overexpression of choline kinase</td>
</tr>
<tr>
<td>11C-acetate</td>
<td>20.3 minutes</td>
<td>PET</td>
<td>Lipid-metabolism agent associated with overexpression of fatty acid synthase</td>
</tr>
<tr>
<td>111In-capromab pendetide</td>
<td>67 hours</td>
<td>Planar/SPECT</td>
<td>Antibody-based PSMA agent</td>
</tr>
<tr>
<td>Emerging PET agents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18F-FACBC</td>
<td>110 minutes</td>
<td>PET</td>
<td>L-Leucine analog amino acid transporter</td>
</tr>
<tr>
<td>18F-FDHT</td>
<td>110 minutes</td>
<td>PET</td>
<td>Androgen analog targets androgen receptor</td>
</tr>
<tr>
<td>64Cu-J591</td>
<td>13 hours</td>
<td>PET</td>
<td>Antibody-based PSMA agent</td>
</tr>
<tr>
<td>89Zr-DFO-J591</td>
<td>78 hours</td>
<td>PET</td>
<td>Antibody-based PSMA agent</td>
</tr>
<tr>
<td>18F-DCFBC</td>
<td>110 minutes</td>
<td>PET</td>
<td>Low-molecular-weight urea-based PSMA inhibitor</td>
</tr>
<tr>
<td>64Ga-PSMA</td>
<td>68 minutes</td>
<td>PET</td>
<td>Low-molecular-weight urea-based PSMA inhibitor</td>
</tr>
<tr>
<td>Promising PET agents in development</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18F-DCFPyL</td>
<td>110 minutes</td>
<td>PET</td>
<td>Low-molecular-weight PSMA-targeting agent</td>
</tr>
<tr>
<td>89Zr-SA20</td>
<td>78 hours</td>
<td>PET</td>
<td>Free PSA-targeting agent</td>
</tr>
<tr>
<td>99mTc-RP527 (bomesin)</td>
<td>6 hours</td>
<td>SPECT</td>
<td>Gastrin-releasing peptide receptor</td>
</tr>
<tr>
<td>64Cu-CB-TE2A-AR06 (bomesin)</td>
<td>13 hours</td>
<td>PET</td>
<td>Gastrin-releasing peptide receptor</td>
</tr>
<tr>
<td>124I-CLR-1404</td>
<td>4 days</td>
<td>PET</td>
<td>Phospholipid ether analog/imaging</td>
</tr>
<tr>
<td>131I-CLR-1404</td>
<td>8 days</td>
<td>SPECT</td>
<td>Phospholipid ether analog/therapy</td>
</tr>
<tr>
<td>18F-glutamate/glutamine</td>
<td>110 minutes</td>
<td>PET</td>
<td>Glutamine analog</td>
</tr>
</tbody>
</table>

Abbreviations: PET, positron-emission tomography; MDP, methylene diphosphonate; DFG, fluordeoxyglucose; FACBC, anti-l-amino-3-18F-fluorocyclobutane-1-carboxylic acid; FDHT, 16,17-fluoro-5α-dihydrotestosterone; DFO, desferrioxamine B; DCFBC, N-[N-(5)-1,3-dicarboxypropyl]carbamoyl]-4-fluorobenzyl-l-cysteine; PSMA, prostate-specific membrane antigen; 18F-DCFPyL, 2-(3-[1-carboxy-5-[6-[18F]fluoropyridine-3-carbonyl]amino]pentyl)-ureido-3-hexanediolic acid; CB-TE2A-AR06, 4,11-bis(carboxymethyl)-1,4,8,11-tetrazazacyclo(6,6,2)hexadecane-PEG, D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH₂; SPECT, single-photon-emission tomography; PSA, prostate-specific antigen.
Current imaging techniques
Traditional anatomic imaging
Conventional approaches for anatomic imaging of prostate cancer include transrectal ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI). The use of transrectal ultrasound for detection of prostate cancer is limited, but it has an essential role in guidance for such interventions as prostate biopsies and radioactive seed placement in primary prostate cancer, as well as for evaluating local recurrence after radical prostatectomy in patients with increasing PSA serum levels. CT is commonly used for initial staging of intermediate- to high-risk disease, to evaluate pelvic lymphadenopathy and extraprostatic disease extension. However, its sensitivity for detection of nodal metastases is only approximately 35%. MRI has many potential applications in prostate cancer, including initial staging, biopsy guidance, surgical planning, radiation planning, and restaging after PSA relapse. Standard anatomic imaging with CT and MRI has limited sensitivity and specificity for detection of primary prostate cancer, and other imaging methods are needed for this purpose. Multiparametric MRI, including diffusion-weighted imaging, dynamic contrast-enhanced MRI, and MR spectroscopy, however, are being found to be very helpful for detection and local staging of untreated prostate cancer, revealing such features as capsular and seminal vesicle invasion, thus discriminating patients with operable disease, or detecting residual or local recurrent prostate cancer.

99mTc-MDP
Prostate cancer most frequently metastasizes to bones with predominantly osteoblastic (sclerotic) metastases. Therefore, the mainstay of imaging for advanced prostate cancer is technetium-99m-labeled bisphosphonate (eg, 99mTc-methylene diphosphonate [MDP]) bone scintigraphy, which is based on the incorporation of the bisphosphonate analog into hydroxyapatite crystals and collagen matrix. This molecular imaging technique is used for initial staging of intermediate- to high-risk disease and for restaging after PSA relapse. It is sensitive and can be used to survey the entire skeleton with a simple planar scan. However, it has limited specificity and is not sensitive enough to detect smaller micrometastases. Single-photon-emission tomography (SPECT) and SPECT/CT have been shown to improve sensitivity in prostate cancer. Quantitative analysis using the bone scan index has recently been shown to be prognostic for survival, and it is under investigation for assessment of treatment response.

18F-NaF
18F-NaF is a diagnostic molecular imaging agent that is used for identification of new bone formation with PET imaging. The uptake mechanism of NaF resembles that of MDP, with better pharmacokinetic characteristics, including very rapid blood clearance, which results in a high bone-to-background ratio and twofold-higher uptake in bone compared to MDP. It has been demonstrated that NaF PET is more sensitive than MDP planar bone scans or SPECT for prostate cancer bone metastases, and incorporation of bone findings from CT with PET/CT results in improved specificity. Figure 2 demonstrates an example of prostate cancer metastases seen on NaF PET compared to an MDP bone scan. Another advantage of NaF PET is the shorter scan time, typically less than 1 hour, compared with a bone scan, resulting in a more efficient workflow, and improved patient convenience. NaF is one of the early skeletal scintigraphy agents, and was approved by the US Food and Drug Administration (FDA) in 1972; however, it was displaced by the arrival of MDP, which provided better resolution. However, with the widespread availability of

Figure 2 18F-NaF PET maximum-intensity projection for a 72-year-old patient with castration-resistant prostate cancer, showing innumerable osseous metastases throughout the skeleton (A). Note that multiple lesions were not identified on the same patient’s 99mTc-MDP bone scan (B) performed 10 days before the 18F-NaF PET scan, but showed fewer metastatic sites (University of Wisconsin PET Center).

Abbreviation: PET, positron-emission tomography.
high-quality PET scanners and the improved logistics for the delivery of $^{18}$F-radiopharmaceuticals, prior logistical and technical limitations to the routine clinical use of NaF PET bone imaging have largely been overcome. At present, NaF PET typically is not performed routinely for clinical use outside large medical centers because of reimbursement issues, but a Center for Medicare and Medicaid Services National Oncologic PET Registry NaF coverage with evidence-development study is currently being performed to evaluate expansion of coverage for NaF for assessing bone metastatic disease.\textsuperscript{15}

$^{18}$F-FDG

$^{18}$F-fluorodeoxyglucose (FDG) PET is an analog of glucose that reflects local rates of glucose consumption by tissues, and shows increased trapping by tumor cells due to increased metabolism and thus glycolytic activity of tumors.\textsuperscript{16} FDG has been by far the most widely used agent for PET imaging for staging and restaging of most cancers.\textsuperscript{17} However, it is limited in primary prostate cancer detection, due to slow growth and low glucose metabolism in early disease, compounded by artifacts created from high bladder activity due to urinary FDG accumulation.\textsuperscript{18} In addition, FDG demonstrates non-specific uptake in prostatitis and benign prostatic hyper trophy (BPH). A study by Hofer et al showed no difference between the $^{18}$F-FDG uptake of benign prostate hyperplasia, prostate carcinoma, postoperative scar, or local recurrence after radical prostatectomy.\textsuperscript{18} However, FDG PET can potentially play an important role in more advanced prostate cancer states. It has been shown to be most useful for evaluating lymph-node and bone metastases, given that it can image the soft tissue and bone simultaneously and provide a quantifiable expression of change using the standardized uptake value.\textsuperscript{19} FDG PET may be useful for restaging after PSA relapse and for assessment of treatment response in CRPC.\textsuperscript{16,19–21} A recent study by Meirelles et al showed that FDG PET was more sensitive than MDP bone scans for bone metastases as a result of CRPC.\textsuperscript{22}

$^{11}$C/$^{18}$F-choline and $^{11}$C-acetate

Prostate cancer cells rely more on fatty acid metabolism than glycolysis with upregulation and increased activity of lipogenic enzymes.\textsuperscript{23} The $^{11}$C/$^{18}$F choline-based ($^{11}$C/$^{18}$F-choline) and $^{11}$C-acetate agents are lipid-metabolism PET agents that have been associated with overexpression of choline kinase\textsuperscript{24,25} and fatty acid synthase,\textsuperscript{26} respectively, in prostate cancer. $^{11}$C/$^{18}$F-choline are taken up in prostate cancer cells through choline transporters and phosphorylated intracellularly by choline kinase.\textsuperscript{27} An example of prostate cancer metastatic disease detection by $^{18}$F-choline ($^{18}$F-FCH) PET/CT is shown in Figure 3. Acetate is incorporated into the membrane lipids due to overexpression of fatty acid synthase. The role of these agents in initial staging is not well established, because of false positives in prostatitis and BPH and false negatives in small (<5 mm) or necrotic tumors.\textsuperscript{28} However, they have promising results for restaging after PSA relapse, with high sensitivity for local recurrence, nodal metastases, and bone metastases.\textsuperscript{29–31} It is worth mentioning that $^{11}$C-choline has been approved for use only at the Mayo Clinic by the FDA for restaging after PSA relapse.\textsuperscript{31–33} Direct comparison of $^{11}$C-acetate and $^{11}$C-choline by Kotzerke et al revealed no clear clinical differences between these agents.\textsuperscript{34}

A recent systematic review of the literature with meta-analysis of $^{11}$C-acetate PET imaging in prostate cancer was done by Beheshhti et al.\textsuperscript{35} For primary tumor detection, pooled diagnostic indices were suboptimal: sensitivity of 75.1\% (range: 69.8\%–79.8\%), and specificity of 75.8\% (range: 72.4\%–78.9\%). This is because of the inability of $^{11}$C-acetate PET imaging to show detect small subcentimeter nodal metastases and high uptake of this radiotracer at sites of BPH that overlapped with prostate cancer uptake. For detection of recurrent tumors, pooled sensitivity was 64\% (59\%–69\%) and specificity of 93\% (83\%–98\%), with higher sensitivity in patients with PSA levels >1 ng/mL and in postprostatectomy compared with external beam radiation therapy patients. Studies comparing $^{11}$C-acetate-based and choline-based PET imaging were reported to be comparable in their analyses, with low sensitivity and relatively high specificity for detection of tumor recurrence and limited value for detection of primary tumors.\textsuperscript{34,35}

In summary, although the available evidence indicates that choline- and acetate-based PET has analytic validity in subsets of patients, proof of clinical validity and clinical utility still must be provided.\textsuperscript{36}

Emerging PET imaging agents

\textbf{$^{18}$F-FACBC}

Amino acids, such as leucine, methionine, and glutamine, are effectively taken up by many tumors because of increased amino acid transport and metabolism. The most promising of these agents for prostate cancer imaging is anti-1-amino-$^{18}$F-fluorocyclobutane-1-carboxylic acid (anti-$^{18}$F-FACBC or $^{18}$F-FACBC), an l-leucine analog whose uptake is related to the activity of two amino acid transporters (ASC and LAT1), which appear to be upregulated in prostate cancer.\textsuperscript{37,38}
18F-FACBC has shown excellent prostate cancer-tumor uptake, with its normal biodistribution favorable for evaluating prostate cancer. Normal uptake is found in the pancreas, liver, and bone marrow, with negligible uptake in the kidneys and very little urinary excretion. An advantage of 18F-FACBC is a relatively long half-life of 109 minutes of an 18F radiotracer compared to 11C-choline or 11C-acetate, which allows PET imaging without an onsite cyclotron. This agent has shown early clinical success in imaging primary and recurrent prostate cancer (prostate bed, lymph nodes and bone metastases), with improved sensitivity compared with 111In-capromab pendetide. Schuster et al performed a prospective study on 50 patients with recurrent prostate cancer, comparing anti-3-18F-FACBC PET/CT with 111In-capromab pendetide SPECT/CT, and demonstrated encouraging results for anti-3-18F-FACBC, which showed a sensitivity of 89%, specificity of 69%, and accuracy of 83%. An example of primary cancer detection by 18F-FACBC is shown in Figure 4.

18F-FDHT
18F-16ß-fluoro-5ß-dihydotestosterone (FDHT) is an androgen analog that is an emerging agent for direct imaging of androgen receptors in prostate cancer. A preclinical study by Bonasera et al showed that FDHT accumulates avidly in the prostate gland of nonhuman primates and has a high binding affinity and selectivity for androgen receptors, and that this uptake was blocked by administration of testosterone. A prospective early study by Dehdashti et al on 20 men with advanced prostate cancer demonstrated that metastatic and recurrent prostate cancer lesions can be detected by PET with FDHT with a sensitivity on a patient-by-patient basis of 63% and on
a lesion-by-lesion basis of 86%. A comparison of $^{18}$F-FDHT and $^{18}$F-FDG PET in prostate cancer metastases is shown in Figure 5. They also showed definite reduction in FDHT uptake in all lesions after patients had been treated with the antiandrogen drug flutamide. In another more recent study by Scher et al, PET imaging of 22 patients revealed reduced FDHT binding after 4 weeks of enzalutamide therapy compared with baseline. This serves as proof of principle for application of molecular imaging agents for prostate cancer drug development and for assessment of individual treatment response.\textsuperscript{16,45,46}

PSMA agents

Several molecular imaging agents have been developed to target the biomarker prostate-specific membrane antigen (PSMA), an integral membrane glycoprotein that is upregulated in prostate cancer, particularly in advanced, hormone-independent, and metastatic disease, and is an active target for the development of imaging agents for prostate cancer.\textsuperscript{49,50}

PSMA is expressed in the prostate at a level of 1,000-fold greater than in other tissues, and eight- to 12-fold higher in prostate cancer over the noncancerous prostate,\textsuperscript{51} particularly in high-grade, hormone-independent, and metastatic disease. These features of PSMA make it an optimal target for developing imaging and therapy strategies for prostate cancer. PSMA agents can be classified into antibodies and antibody fragments and low-molecular-weight compounds that include two types: ureas and phosphoramidates.\textsuperscript{52}

Antibody-based PSMA agents

The first imaging method using PSMA as an antigen target was the antibody capromab pendetide (ProstaScint\textsuperscript{®}), which...
is labeled by $^{\text{111}}\text{In}$ (In-capromab pendetide), and is the only PSMA-based imaging agent that has gained FDA approval to date. Clinical evaluation of $^{\text{111}}\text{In}$-capromab pendetide for detection of prostate cancer recurrence outside the prostate fossa in the biochemical recurrence setting has been disappointing, and overall has been of limited clinical utility for prostate cancer management. Some of the issues inherent with the limitation of this agent are the targeting of the internal epitope of PSMA and the use of an intact antibody that has prolonged blood-pool retention, leading to high background signals and subsequently reduced detection rates, as well as the inherently lower spatial resolution of $^{\text{111}}\text{In}$ planar and SPECT scintigraphic techniques when compared to PET. Furthermore, results obtained with ProstaScint have been controversial, with some reports claiming no advantage in using the scan in patients with rising PSA postprostatectomy.

Second- and third-generation humanized PSMA-binding antibodies have been more successful at targeting this promising prostate cancer biomarker. Humanized monoclonal antibody J591 demonstrated superior targeting compared with capromab pendetide, due to targeting of the extracellular epitope of PSMA, with excellent binding characteristics and tumor-to-background ratio in prostate cancer xenografts. One of the J591-based agents is $^{\text{64}}\text{Cu}$-J591, which has been studied in animals but not in humans, and demonstrated PSMA upregulation after androgen blockade. Recent success in imaging with $^{\text{89}}\text{Zr}$-labeled J591 has been observed in preclinical models, with excellent tumor uptake and retention by the PET agent $^{\text{89}}\text{Zr}$-desferrioxamine B (DFO)-J591 ($^{\text{89}}\text{Zr}$-J591). The first report of $^{\text{89}}\text{Zr}$-J591 PET in localized prostate cancer cases was reported by Osborne et al in 2013. In this pilot study on eleven patients, they found that $^{\text{89}}\text{Zr}$-J591 bound to tumor foci in situ and PET identified primarily Gleason score 7 or greater and larger tumors, likely corresponding to clinically significant disease warranting definitive therapy. Results from another recent pilot study were reported by Pandit-Taskar et al in ten patients to evaluate biodistribution, kinetics, radiation dosimetry and lesion detectability by $^{\text{89}}\text{Zr}$-J591, and showed excellent targeting of prostate cancer lesions. They reported that all $^{\text{89}}\text{Zr}$-J591-positive lesions were histologically confirmed as prostate cancer, and a nodal disease in two patients was identified by this imaging method only, whereas other imaging (FDG PET and CT) was negative.

**Low molecular weight-based PSMA agents**

$^{\text{18}}\text{F}$-DCFBC

A low-molecular-weight, urea-based inhibitor of PSMA, $^{\text{18}}\text{F}$-$\text{N}-[\text{V}-(\text{S})-\text{1,3-dicarboxypropyl}]-\text{carbamoyl}]-4$-fluorobenzyl-$\text{L}$-cysteine ($^{\text{18}}\text{F}$-DCFBC) was the first agent for low-molecular-weight PSMA-targeted PET imaging of
prostate cancer. Initial preclinical studies in prostate cancer mouse-xenograft studies by Mease et al demonstrated high tumor-to-background ratio and rapid clearance from nontarget sites, with a target-to-background ratio of 20:1 at 120 minutes after injection. The time-activity curves indicated that $^{18}$F-DCFBC had achieved equilibrium by 120 minutes, and had begun to decrease in concentration at the target site. It has been developed and evaluated in a first-in-human clinical trial for progressive metastatic prostate cancer. Bone and soft-tissue metastases were successfully visualized by $^{18}$F-DCFBC PET, as also were probable early bone lesions that were not seen on CT or MDP bone scans. Figure 6 demonstrates bone and nodal metastatic disease detection by $^{18}$F-DCFBC PSMA PET. These early promising results, in conjunction with appropriate pharmacokinetics and dosimetry, lay the groundwork for further evaluation in larger prospective clinical trials of $^{18}$F-DCFBC as a prostate cancer PET imaging agent.

### $^{68}$Ga-PSMA

Another urea-based inhibitor of PSMA, Glu-NH-CO-NH-Lys-(Ahx)-[Ga(HBED-CC)] ($^{68}$Ga-PSMA) is another promising low-molecular-weight PSMA-based imaging PET agent. Afshar-Oromieh et al evaluated the biodistribution and tumor uptake of $^{68}$Ga-PSMA in 37 patients, and showed excellent contrast between tumor lesions and background as early as 1 hour postinjection, with high detection rates even at low PSA levels. Later images at 3 hours showed better contrast, with a median tumor-to-background ratio of 28:1. Another recent study comparing $^{68}$Ga-PSMA with $^{18}$F-fluorocholine with biochemical relapse of prostate cancer in 37 patients within a 10-day time window was able to detect more lesions and higher signal-to-background noise using $^{68}$Ga-PSMA compared with $^{18}$F-fluorocholine (78 versus 56, respectively; $P=0.04$).

### Promising PET imaging agents in development $^{18}$F-DCFPyL

A second-generation low-molecular-weight $^{18}$F-fluorine-labeled PSMA targeting agent, 2-(3-[1-carboxy-5-[(6-$^{18}$F)fluoropyridine-3-carboxyl]amino]pentyl)-ureido)pentanedioic acid ($^{18}$F-DCFPyL), has also been developed to improve tumor uptake and clearance from nontarget sites. Preclinical studies have demonstrated a high tumor-to-background ratio at 2 hours postinjection of 39.4±4.4% injected dose (ID)/g within PSMA-expressing tumor xenografts. An animal study on mice by Chen et al showed high and prolonged PSMA-selective uptake, with very low nontarget uptake and rapid clearance from normal organs. They demonstrated that the uptake in PSMA+ PC-3 PIP tumor was 46.7±5.8% ID/g at 30 minutes postinjection and 36.6±4.3% ID/g at 4 hours. A first-in-man clinical trial of this radiotracer is currently being conducted at Johns Hopkins University.

### Free prostate-specific antigen imaging

A novel radiotracer that targets free PSA, $^{90}$Zr-labeled 5A10 has been developed and studied preclinically by Ulmert et al. They demonstrated that $^{90}$Zr-5A10 is localized to multiple androgen receptor- and PSA-positive prostate cancer models, with a decline in free PSA synthesis induced by antiandrogen therapy in a clinically validated xenograft model of CRPC. This new radiotracer may offer more accurate staging, given
it specifically targets prostate cancer osseous metastases rather than nonmalignant skeletal pathologies, unlike bone scintigraphy, which is less specific. However, one of the limitations of \(^{89}\)Zr-5A10 in prostate cancer is overexpression of PSA also in benign pathologies of the prostate; therefore, local detection of primary prostate cancer might be challenging.

**Bombesin-based agents**

Bombesin-like peptides, such as gastrin-releasing peptide (GRP), have been shown to play a role in oncology. The GRP receptor (GRPr), a member of the bombesin-receptor family, is physiologically expressed in the gastrointestinal tract and central nervous system, and is found to be overexpressed in different malignant tumors, but most consistently in prostate cancer. Therefore, it is considered a promising target for sensitive and specific imaging target for prostate cancer. A study by Markwalder and Reubi on 50 patients with primary prostate cancer or primary urinary bladder cancer demonstrated high density of GRPrs not only in invasive prostatic carcinomas but also in prostatic intraepithelial neoplasia. This is in contrast to an absence or low density of GRPrs in nonneoplastic prostatic tissue, in particular benign prostatic hyperplasia.

Different bombesin-receptor ligands have been tested preclinically, but a limited number of these have been evaluated in humans. An example is the \(^{99m}\)Tc-labeled bombesin agonist \(^{99m}\)Tc-RP527, tested in patients with breast and prostate cancers, which however showed some limitation due to high gastrointestinal uptake, which may limit the detection of metastatic prostate cancer. GRPr antagonists were studied in preclinical models of prostate cancer, and showed higher tumor uptake and lower gastrointestinal uptake than the agonists. One of the studied GRPr antagonists, \(^{64}\)Cu-CB-TE2A-AR06 [(\(^{64}\)Cu-4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo(6.6.2)hexadecane)-PEG \(_4\)-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH\(_2\)], demonstrated the most favorable tumor uptake and tumor-to-background contrast. A recent pilot clinical study by Wieser et al on four patients with newly diagnosed prostate cancer without prior therapy showed favorable biodistribution and high tumor uptake of GRPr antagonists that were rapidly cleared from organs with physiologic GRPr expression and retained significantly longer in human prostate cancers, with an example seen in Figure 7. This resulted in steadily increasing tumor-to-background ratios over time. Studies in a larger number of patients will be necessary in order to determine the sensitivity

---

**Figure 7** (A–C) PET/CT gastrin-releasing peptide-receptor or bombesin-receptor imaging with \(^{64}\)Cu-CB-TE2A-AR06, showing focal uptake of primary prostate cancer (red arrows), below urinary bladder activity.

**Abbreviations:** PET, positron-emission tomography; CT, computed tomography; CB-TE2A-AR06, 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo(6.6.2)hexadecane)-PEG \(_4\)-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH\(_2\).
of $^{68}$Cu-CB-TE2A-AR06 PET/CT. $^{68}$Ga-based GRPr PET imaging radiotracers are also being developed.

**Phospholipid ether analogs**

Counsell et al\(^{67}\) and Pinchuk et al\(^{68}\) have developed multiple radiolabeled versions of phospholipid ether analogs that enter malignant cells via overexpressed membrane-lipid rafts. One of the emerging phospholipid ether analogs is CLR1404, which has promising applications in oncology, including prostate cancer. Radiiodine labeling of this agent with $^{124}$I and $^{131}$I enables cancer imaging and therapy, respectively. This agent shows significant clearance from organs, with prolonged tumor retention for days to weeks postinjection, enabling excellent tumor-to-background ratios. In contrast to $^{18}$F-FDG, CLR1404 shows minimal or even no physiologic uptake in the brain, which enables visualization of brain metastases with excellent contrast.

A recent preliminary study by Pickhardt et al\(^{70}\) on 22 patients with different solid tumors, including three patients with prostate cancer, showed preferential uptake of $^{124}$I- and $^{131}$I-labeled CLR1404 within a variety of metastatic foci, with persistent tumor retention coupled with progressive washout of background activity. Further clinical trials with this new agent are under way.

$^{11}$C/$^{18}$F-glutamate/glutamine

The amino acid glutamine is the most abundant nonessential amino acid in the human body, and has been recognized as an important tumor nutrient. Glutamine enters the cells via glutamine transporters and is converted by glutaminase to glutamate, leading to high intracellular concentrations of glutamate.\(^{71,72}\) Since glutamine metabolism is upregulated in many tumors, using radiolabeled glutamine and its related derivatives in tumor imaging is appropriate. The ability of some tumors preferentially to use glutamine rather than glucose to satisfy their metabolic needs suggests that $^{18}$F-FDG PET-negative tumors may have elevated rates of glutaminolysis. Several $^{11}$C- and $^{18}$F-labeled glutamine analogs have been used as PET tumor-imaging agents in humans.\(^{73}\) An animal study by Qu et al\(^{73}\) using $^{11}$C-labeled glutamate (L-[5-$^{11}$C]-glutamate) showed maximum tumor uptake at 20 minutes after injection that remained consistent throughout the 60-minute scan time with little to no washout, suggesting that the radioactivity was taken up and trapped in the tumor tissue. $^{18}$F-labeled glutamine analogs are now emerging for tumor imaging, including prostate cancer, which has a longer physical half-life (110 minutes) compared to $^{11}$C-labeled glutamine analogs, and may provide a more convenient and useful tool for mapping glutamine metabolism.

**Multimodality PET/MRI**

Simultaneous acquisition of multiparametric MR and PET images has been recently introduced that incorporates the advantages of both PET and MRI together and offers simultaneous instead of sequential acquisitions. PET/MRI provides combined structural, metabolic, and functional imaging information with improved soft-tissue contrast and availability of sophisticated MRI sequences, such as diffusion and perfusion imaging, functional MRI, and MR spectroscopy. This in turn improves the accuracy in the detection and staging of untreated primary prostate cancer, and detection of residual or local recurrence. Furthermore, the use of PET/MRI would result in a significant decrease in radiation exposure.\(^{9}\)

**Conclusion**

As management of prostate cancer is moving toward more personalized patient-adapted therapy, there is an increasing demand for more specialized molecular imaging beyond $^{99m}$Tc-MDP scintigraphy. In this article, we have reviewed many existing and emerging molecular imaging agents for prostate cancer in different stages of development. Many of these agents have promising potential for more specific detection of primary and metastatic disease for facilitating a mechanism-based personalized approach to disease management.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


